false Q1 0000890394 --12-31 http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member true true P4Y P3Y P4Y P3Y 0.34 0.79 19769000 5241000 P8Y2M4D P1Y5M26D P2Y5M1D P4Y4M24D P3Y P8Y1M24D 1.57 15.00 25.60 144.00 410.0 1.57 14.99 25.59 143.99 409.99 924.00 924.00 2023-01-31 2023-10-31 0000890394 2022-01-01 2022-03-31 xbrli:shares 0000890394 2022-05-09 iso4217:USD 0000890394 2022-03-31 0000890394 2021-12-31 iso4217:USD xbrli:shares 0000890394 us-gaap:ProductMember 2022-01-01 2022-03-31 0000890394 us-gaap:ProductMember 2021-01-01 2021-03-31 0000890394 prso:RoyaltyAndOtherMember 2022-01-01 2022-03-31 0000890394 prso:RoyaltyAndOtherMember 2021-01-01 2021-03-31 0000890394 2021-01-01 2021-03-31 0000890394 us-gaap:CommonStockMember 2021-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000890394 us-gaap:RetainedEarningsMember 2021-12-31 0000890394 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000890394 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000890394 us-gaap:CommonStockMember 2022-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000890394 us-gaap:RetainedEarningsMember 2022-03-31 0000890394 us-gaap:CommonStockMember 2020-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000890394 us-gaap:RetainedEarningsMember 2020-12-31 0000890394 2020-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000890394 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000890394 us-gaap:CommonStockMember 2021-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000890394 us-gaap:RetainedEarningsMember 2021-03-31 0000890394 2021-03-31 xbrli:pure 0000890394 prso:ScientificResearchAndExperimentalDevelopmentMember 2022-01-01 2022-03-31 0000890394 srt:MinimumMember 2022-01-01 2022-03-31 0000890394 srt:MaximumMember 2022-01-01 2022-03-31 0000890394 2019-01-01 2019-12-31 0000890394 prso:EscrowSharesMember 2022-01-01 2022-03-31 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2021-01-01 2021-03-31 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000890394 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-03-31 0000890394 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000890394 us-gaap:WarrantMember 2021-01-01 2021-03-31 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2022-01-01 2022-03-31 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2022-03-31 0000890394 prso:PerasoSharesMember 2022-03-31 0000890394 prso:EscrowSharesMember 2022-03-31 utr:D 0000890394 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000890394 us-gaap:CustomerRelationshipsMember 2021-12-31 0000890394 us-gaap:CashAndCashEquivalentsMember 2022-03-31 0000890394 us-gaap:ShortTermInvestmentsMember 2022-03-31 0000890394 prso:LongTermInvestmentsMember 2022-03-31 0000890394 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000890394 us-gaap:ShortTermInvestmentsMember 2021-12-31 0000890394 prso:LongTermInvestmentsMember 2021-12-31 0000890394 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0000890394 stpr:CA 2022-01-01 2022-03-31 0000890394 prso:WaterlooCanadaMember 2022-01-01 2022-03-31 0000890394 prso:TorontoCanadaMember 2022-01-01 2022-03-31 0000890394 2022-03-01 prso:Segment 0000890394 srt:NorthAmericaMember 2022-01-01 2022-03-31 0000890394 srt:NorthAmericaMember 2021-01-01 2021-03-31 0000890394 country:HK 2022-01-01 2022-03-31 0000890394 country:HK 2021-01-01 2021-03-31 0000890394 country:TW 2022-01-01 2022-03-31 0000890394 country:TW 2021-01-01 2021-03-31 0000890394 country:JP 2022-01-01 2022-03-31 0000890394 prso:RestOfWorldMember 2022-01-01 2022-03-31 0000890394 prso:RestOfWorldMember 2021-01-01 2021-03-31 0000890394 prso:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000890394 prso:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2022-01-01 2022-03-31 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2021-01-01 2021-12-31 prso:Customer 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2022-03-31 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2021-12-31 0000890394 prso:EquityIncentivePlan2010Member 2022-01-01 2022-03-31 0000890394 prso:StockIncentivePlan2019Member 2022-03-31 0000890394 prso:StockIncentivePlan2019Member 2021-11-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember srt:MinimumMember 2022-01-01 2022-03-31 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember srt:MaximumMember 2022-01-01 2022-03-31 0000890394 prso:NewEmployeesMember 2022-03-31 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2021-01-01 2021-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2021-12-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-01-01 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0000890394 prso:RangeOfExercisePriceOneMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:RangeOfExercisePriceTwoMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:RangeOfExercisePriceThreeMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:RangeOfExercisePriceFourMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:RangeOfExercisePriceFiveMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:RangeOfExercisePriceSixMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-03-31 0000890394 prso:RangeOfExercisePriceOneMember prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:RangeOfExercisePriceTwoMember prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:RangeOfExercisePriceThreeMember prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:RangeOfExercisePriceFourMember prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:RangeOfExercisePriceFiveMember prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:RangeOfExercisePriceSixMember prso:EmployeeAndDirectorsStockOptionsMember 2022-03-31 0000890394 prso:CommonStockOneMember 2022-03-31 0000890394 prso:CommonStockTwoMember 2022-03-31 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-02-05 2021-02-05 iso4217:CAD 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-03-05 2021-03-05 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-09-17 2021-09-17 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2022-01-01 2022-03-31 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2022-03-31 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2020-11-30 2021-03-05 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-12-16 2021-12-16 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-01-01 2021-03-31 0000890394 us-gaap:ConvertibleDebtMember 2021-01-01 2021-03-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark one)

| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-32929

PERASO INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 77-0291941
(State or other jurisdiction |  | (I.R.S. Employer
of Incorporation or organization) |  | Identification Number)

2309 Bering Drive

San Jose, California 95131

(Address of principal executive office and zip code)

(408) 418-7500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | PRSO | The Nasdaq Stock Market, LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer | ☐ |  | Accelerated filer | ☐
Non-accelerated filer | ☒ |  | Smaller reporting company | ☒
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 21,607,633 as of May 9, 2022.

PERASO INC.

FORM 10-Q

March 31, 2022

PART I — | FINANCIAL INFORMATION | 3
Item 1. | Financial Statements (Unaudited): | 3
| Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 | 3
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021 | 4
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 and 2021 | 5
| Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 | 6
| Notes to Condensed Consolidated Financial Statements | 7
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22
Item 4. | Controls and Procedures | 28
PART II — | OTHER INFORMATION | 28
Item 1. | Legal Proceedings | 28
Item 1A. | Risk Factors | 28
Item 6. | Exhibits | 29
| Signatures | 30

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

PERASO INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

|  | March 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
|  | (unaudited) |  |  |  |  |
ASSETS |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 3,791 |  |  | $ | 5,893 |
Short-term investments |  |  | 5,993 |  |  |  | 9,267 |
Accounts receivable, net |  |  | 2,106 |  |  |  | 2,436 |
Inventories |  |  | 4,521 |  |  |  | 3,824 |
Tax credits and receivables |  |  | 1,117 |  |  |  | 1,099 |
Prepaid expenses and other |  |  | 1,333 |  |  |  | 1,159 |
Total current assets |  |  | 18,861 |  |  |  | 23,678 |
Long-term investments |  |  | 2,399 |  |  |  | 2,928 |
Property and equipment, net |  |  | 2,042 |  |  |  | 2,349 |
Intangible assets, net |  |  | 7,852 |  |  |  | 8,355 |
Goodwill |  |  | 9,946 |  |  |  | 9,946 |
Right-of-use lease asset, net |  |  | 770 |  |  |  | 617 |
Other |  |  | 78 |  |  |  | 78 |
Total assets |  | $ | 41,948 |  |  | $ | 47,951 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,941 |  |  | $ | 1,937 |
Accrued expenses and other |  |  | 2,373 |  |  |  | 2,903 |
Deferred revenue |  |  | 361 |  |  |  | 375 |
Short-term lease liability |  |  | 422 |  |  |  | 379 |
Total current liabilities |  |  | 5,097 |  |  |  | 5,594 |
Long-term lease liability |  |  | 411 |  |  |  | 288 |
Total liabilities |  |  | 5,508 |  |  |  | 5,882 |
Commitments and contingencies (Note 5) |  |  |  |  |  |  |  |
Stockholders’ equity |  |  |  |  |  |  |  |
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding |  |  | — |  |  |  | — |
Common stock, $0.001 par value; 120,000 shares authorized; 21,588 shares and 21,579 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively |  |  | 22 |  |  |  | 22 |
Additional paid-in capital |  |  | 160,408 |  |  |  | 159,246 |
Accumulated other comprehensive loss |  |  | (37 | ) |  |  | — |
Accumulated deficit |  |  | (123,953 | ) |  |  | (117,199 | )
Total stockholders’ equity |  |  | 36,440 |  |  |  | 42,069 |
Total liabilities and stockholders’ equity |  | $ | 41,948 |  |  | $ | 47,951 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share data)

|  | Three Months Ended |
|  | March 31, |
|  | 2022 |  |  | 2021 |
Net revenue |  |  |  |  |  |  |  |
Product |  | $ | 3,204 |  |  | $ | 1,051 |
Royalty and other |  |  | 199 |  |  |  | 50 |
Total net revenue |  |  | 3,403 |  |  |  | 1,101 |
Cost of net revenue |  |  | 1,590 |  |  |  | 619 |
Gross profit |  |  | 1,813 |  |  |  | 482 |
Operating expenses |  |  |  |  |  |  |  |
Research and development |  |  | 6,003 |  |  |  | 2,787 |
Selling, general and administrative |  |  | 2,546 |  |  |  | 1,307 |
Total operating expenses |  |  | 8,549 |  |  |  | 4,094 |
Loss from operations |  |  | (6,736 | ) |  |  | (3,612 | )
Interest expense |  |  | — |  |  |  | (513 | )
Other expense, net |  |  | (18 | ) |  |  | (32 | )
Net loss |  | $ | (6,754 | ) |  | $ | (4,157 | )
Other comprehensive loss, net of tax: |  |  |  |  |  |  |  |
Net unrealized loss on available-for-sale securities |  |  | (37 | ) |  |  | — |
Comprehensive loss |  | $ | (6,791 | ) |  | $ | (4,157 | )
Net loss per share |  |  |  |  |  |  |  |
Basic and diluted |  | $ | (0.34 | ) |  | $ | (0.79 | )
Shares used in computing net loss per share |  |  |  |  |  |  |  |
Basic and diluted |  |  | 19,769 |  |  |  | 5,241 |

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands)

|  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | Additional |  |  | Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-In |  |  | Comprehensive |  |  | Accumulated |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Deficit |  |  | Total |
Balance as of December 31, 2021 |  |  | 21,579 |  |  | $ | 22 |  |  | $ | 159,246 |  |  | $ | — |  |  | $ | (117,199 | ) |  | $ | 42,069 |
Issuance of common stock under stock plan, net |  |  | 9 |  |  |  | — |  |  |  | (9 | ) |  |  | — |  |  |  | — |  |  |  | (9 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 1,171 |  |  |  | — |  |  |  | — |  |  |  | 1,171 |
Unrealized loss on available-for-sale securities |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (37 | ) |  |  | — |  |  |  | (37 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,754 | ) |  |  | (6,754 | )
Balance as of March 31, 2022 |  |  | 21,588 |  |  | $ | 22 |  |  | $ | 160,408 |  |  | $ | (37 | ) |  | $ | (123,953 | ) |  | $ | 36,440 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  | Additional |  |  | Other |  |  |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-In |  |  | Comprehensive |  |  | Accumulated |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Deficit |  |  | Total |
Balance as of December 31, 2020 |  |  | 5,241 |  |  | $ | 5 |  |  | $ | 102,361 |  |  | $ | — |  |  | $ | (106,287 | ) |  | $ | (3,921 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 1,177 |  |  |  | — |  |  |  | — |  |  |  | 1,177 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,157 | ) |  |  | (4,157 | )
Balance as of March 31, 2021 |  |  | 5,241 |  |  | $ | 5 |  |  | $ | 103,538 |  |  | $ | — |  |  | $ | (110,444 | ) |  | $ | (6,901 | )

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

|  | Three Months Ended |
|  | March 31, |
|  | 2022 |  |  | 2021 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net loss |  | $ | (6,754 | ) |  | $ | (4,157 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 776 |  |  |  | 277 |
Stock-based compensation |  |  | 1,171 |  |  |  | 1,177 |
Change in fair value of warrant liability |  |  | — |  |  |  | 39 |
Amortization of debt discount |  |  | — |  |  |  | 348 |
Accrued interest expense |  |  | — |  |  |  | 165 |
Amortization of lease right-of-use assets |  |  | 121 |  |  |  | 60 |
Change in operating lease liabilities |  |  | (107 | ) |  |  | (58 | )
Other |  |  | 152 |  |  |  | 9 |
Changes in assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 331 |  |  |  | 688 |
Inventories |  |  | (698 | ) |  |  | 155 |
Tax credits and receivables |  |  | (17 | ) |  |  | (246 | )
Prepaid expenses and other assets |  |  | (175 | ) |  |  | 121 |
Accounts payable |  |  | 4 |  |  |  | 133 |
Deferred revenue and other liabilities |  |  | (544 | ) |  |  | 37 |
Net cash used in operating activities |  |  | (5,740 | ) |  |  | (1,252 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | (76 | ) |  |  | (9 | )
Purchases of intangible assets |  |  | (20 | ) |  |  | — |
Proceeds from maturities of marketable securities |  |  | 4,240 |  |  |  | — |
Purchases of marketable securities and investments |  |  | (497 | ) |  |  | — |
Net cash provided by (used in) investing activities |  |  | 3,647 |  |  |  | (9 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Taxes paid to net share settle equity awards |  |  | (9 | ) |  |  | — |
Net proceeds from loan facility |  |  | — |  |  |  | 552 |
Net cash provided by (used in) financing activities |  |  | (9 | ) |  |  | 552 |
Net decrease in cash and cash equivalents |  |  | (2,102 | ) |  |  | (709 | )
Cash and cash equivalents at beginning of period |  |  | 5,893 |  |  |  | 1,711 |
Cash and cash equivalents at end of period |  | $ | 3,791 |  |  | $ | 1,002 |
Supplemental disclosure: |  |  |  |  |  |  |  |
Recognition of right-of-use asset and lease liability |  | $ | 274 |  |  | $ | — |
Unrealized loss on securities |  | $ | 37 |  |  | $ | — |

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

PERASO INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company and Summary of Significant Accounting Policies

Peraso Inc., formerly known as MoSys, Inc. (the Company), was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company is a fabless semiconductor company specializing in the development of mmWave technology, including 60GHz and 5G products, and derives revenue from selling semiconductor devices, licensing of intellectual property (IP) and performance of non-recurring engineering services (NRE). The Company also manufactures and sells memory semiconductor devices that enable fast, intelligent data access and decision making for a wide range of markets.

On September 14, 2021, the Company and its subsidiaries, 2864552 Ontario Inc. (Callco) and 2864555 Ontario Inc. (Canco), entered into an Arrangement Agreement (the Arrangement Agreement) with Peraso Technologies Inc. (Peraso Tech), a corporation existing under the laws of the province of Ontario, to acquire all of the issued and outstanding common shares of Peraso Tech (the Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures and common share purchase warrants of Peraso Tech, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario). On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, the Arrangement was completed and, the Company changed its name to “Peraso Inc.” and began trading on the Nasdaq Stock Market (the Nasdaq) under the symbol “PRSO.”

For accounting purposes, the legal subsidiary, Peraso Tech, has been treated as the accounting acquirer and the Company, the legal parent, has been treated as the accounting acquiree. The transaction was accounted for as a reverse acquisition in accordance with Accounting Standards Codification (ASC) No. 805, Business Combinations (ASC 805). Accordingly, these condensed consolidated financial statements are a continuation of Peraso Tech’s consolidated financial statements prior to December 17, 2021 and exclude the statements of operations and comprehensive loss, statement of stockholders’ equity (deficit) and statements of cash flows of the Company prior to December 17, 2021. See Note 2 for additional disclosure.

The accompanying condensed consolidated financial statements of the Company have been prepared without audit.

The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other future period.

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.

7

Risks and Uncertainties

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.

COVID-19

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Material estimates may include assumptions made in determining reserves for uncollectible receivables, inventory write-downs, impairment of long-term assets, purchase price allocations, valuation allowance on deferred tax assets, accruals for potential liabilities and assumptions made in valuing equity instruments. Actual results could differ from those estimates.

Cash Equivalents and Investments

The Company has invested its excess cash in money market accounts, certificates of deposit, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term and long-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income (loss). Realized gains and losses and declines in the value judged to be other-than-temporary are included in the other income, net line item in the condensed consolidated statements of operations. The cost of securities sold is based on the specific identification method.

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.

8

Level 2—Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities include cash equivalents and available-for-sale securities, which consisted primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.

Level 3—Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

Allowance for Doubtful Accounts

The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts receivable was zero as of March 31, 2022 and approximately $61,000 as of December 31, 2021.

Inventories

The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. Costs of inventories primarily consisted of material and third party assembly costs. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded write-downs of inventory of approximately $114,000 during the three months ended March 31, 2022, and recorded no write-downs of inventory during the three months ended March 31, 2021.

Tax Credits and Receivables

The Company is registered for the Canadian federal and provincial goods and services taxes. As such, the Company is obligated to collect from third parties, and is entitled to claim sales taxes paid on its expenses and capital expenditures incurred in Canada.

In addition, as a Canadian Controlled Private Corporation (CCPC), the Company is also a part of the Scientific Research and Experimental Development (SR&ED) Program, which uses tax incentives to encourage Canadian businesses of all sizes and in all sectors to conduct research and development (R&D) in Canada. As a part of the program, the Company may be entitled to a receivable in the form of tax credit or incentive. The Company records refundable tax credits as a reduction of expense and receivable when the Company can reasonably estimate the amounts and it is more likely than not, they will be received.

A government refund or subsidy that is compensation for expenses or losses already incurred, or for which there are no future related costs, is recognized in the statement of operations in the period in which it becomes receivable.

9

As of December 17, 2021, Peraso Tech ceased to be a CCPC and is no longer eligible for the expenditure refund program. However, it is eligible for a tax credit of 15% on qualified SR&ED expenditures. Unused tax credits can be carried back three years or forward for 20 years

Intangible and Long-lived Assets

Intangible assets are recorded at cost and amortized on a straight-line method over their estimated useful lives of three to ten years. The Company regularly reviews the carrying value and estimated lives of its long-lived assets and finite-lived intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.

Goodwill

The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference.

Leases

ASC No. 842, Leases (ASC 842) requires an entity to recognize a right-of-use asset and a lease liability for all leases with terms longer than 12 months. The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification of its existing leases.

Revenue Recognition

The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) ASC Topic 606, Revenue from Contracts with Customers, and its amendments (ASC 606). As described below, the analysis of contracts under ASC 606 supports the recognition of revenue at a point in time, resulting in revenue recognition timing that is materially consistent with the Company’s historical practice of recognizing product revenue when title and risk of loss pass to the customer.

The Company generates revenue primarily from sales of integrated circuits and module products, performance of engineering services and licensing of its intellectual property. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

10

Product revenue

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less.

The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

License and other

The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are received in the subsequent quarter. The Company also generates revenue from licensing its technology. The Company recognizes license fees as revenue at the point of time when the control of the license has been transferred and the Company has no continuing performance obligations to the customer.

Engineering services revenue

Engineering and development contracts with customers generally contain a single performance obligation that is delivered over time. Revenue is recognized using an output method that is consistent with the satisfaction of the performance obligation as a measure of progress.

Contract liabilities – deferred revenue

The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. As of December 31, 2021, contract liabilities were in a current position and included in deferred revenue.

During the three months ended March 31, 2022, the Company recognized approximately $15,000 of revenue that had been included in deferred revenue as of December 31, 2021.

See Note 6 for disaggregation of revenue by geography.

The Company does not have significant financing components, as payments from customers are typically due within 60 days of invoicing, and the Company has elected the practical expedient to net value financing components that are less than one year. Shipping and handling costs are generally incurred by the customer, and, therefore, are not recorded as revenue.

Cost of Net Revenue

Cost of net revenue consists primarily of direct and indirect costs of product sales.

Government Subsidies

A grant or subsidy that is compensation for expenses or losses already incurred, or for which there are no future related costs, is recognized in the statement of operations in the period in which it becomes receivable.

Starting in 2020, certain Canadian businesses, which experienced a drop in revenue during the COVID-19 pandemic, became eligible for a rent and wage subsidy from the government. The Company’s subsidiary, Peraso Tech, began receiving this subsidy on a monthly basis beginning in the fourth quarter of 2020.

11

During the three months ended March 31, 2021, the Company recognized payroll subsidies of $425,525 as a reduction in the associated wage costs and rent subsidies of $77,780 as a reduction of operating expenses in the condensed consolidated statement of operations.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees. The Company accounts for such grants based on ASC No. 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the vesting period. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.

Foreign Currency Transactions

The functional currency of the Company is the U.S dollar. All foreign currency transactions are initially measured and recorded in an entity’s functional currency using the exchange rate on the date of the transaction. All monetary assets and liabilities are remeasured at the end of each reporting period using the exchange rate at that date. All non-monetary assets and related expense, depreciation or amortization are not subsequently remeasured and are measured using the historical exchange rate. An average exchange rate may be used to recognize income and expense items earned or incurred evenly over a period. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in the statement of operations, except for the gains and losses arising from the conversion of the carrying amount of the foreign currency denominated convertible preferred shares into the functional currency that are presented as adjustment to the net loss to arrive at net loss attributable to common stockholders.

Per Share Amounts

Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and exercise of warrants.

The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands):

|  | March 31, |
|  | 2022 |  |  | 2021 |
Escrow shares |  |  | 1,815 |  |  |  | — |
Options to purchase common stock |  |  | 1,545 |  |  |  | 1,042 |
Unvested restricted common stock units |  |  | 75 |  |  |  | — |
Convertible debt |  |  | — |  |  |  | 3,272 |
Warrants |  |  | 134 |  |  |  | 375 |
Total |  |  | 3,569 |  |  |  | 4,689 |

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses. This ASU added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years

12

for smaller reporting companies. The Company is still evaluating the impact of this accounting guidance on its results of operations and financial position.

In August 2020, the FASB issued ASU No. 2020-06 (ASU 2020-06), Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that: i) are not clearly and closely related to the host contract, ii) meet the definition of a derivative, and iii) do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The ASU also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for the Company January 1, 2024, and early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. The Company is currently evaluating what effect(s) the adoption of ASU 2020-06 may have on its financial statements, but the Company does not believe the impact of the ASU will be material to its financial position, results of operations and cash flows. The effect will largely depend on the composition and terms of the Company’s financial instruments at the time of adoption.

Note 2: Business Combination

Arrangement

As discussed in Note 1, on September 14, 2021, the Company and its newly formed subsidiaries Callco and Canco entered into the Arrangement Agreement with Peraso Tech.

On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, including approvals from the stockholders of the Company and Peraso Tech, the Arrangement was completed.

Securities Conversion

Pursuant to the completion of the Arrangement, each Peraso Share that was issued and outstanding immediately prior to December 17, 2021 was converted into the right to receive 0.045239122387267 (the Exchange Ratio) newly issued shares of common stock of the Company or shares of Canco, which are exchangeable for shares of the Company’s common stock (Exchangeable Shares) at the election of each former Peraso Tech stockholder. In addition, all of Peraso Tech’s outstanding stock options and other securities exercisable or exchangeable for, or convertible into, and any other rights to acquire Peraso Shares were exchanged for securities exercisable or exchangeable for, or convertible into, or other rights to acquire the Company’s common stock. Immediately following the completion of the Arrangement, the former security holders of Peraso Tech owned approximately 61%, on a fully-diluted basis, of the Company’s common stock, and the former shareholders of Peraso Tech, as a group, obtained control of the Company. While the Company was the legal acquirer of Peraso Tech, Peraso Tech was deemed to be the acquirer for accounting purposes.

In addition, pursuant to the terms of the Arrangement Agreement, (i) certain warrants to purchase Peraso Shares outstanding immediately prior to the closing of the Arrangement were exercised in consideration for the issuance of Peraso Shares; (ii) each convertible debenture of Peraso Tech outstanding immediately prior to the closing of the Arrangement and all principal and accrued but unpaid interest thereon was converted into Peraso Shares at a conversion price equal to the conversion price set out in each such debenture; and (iii) each outstanding option to purchase Peraso Shares (each, a Peraso Option) was exchanged for a replacement option to purchase such number of shares of common stock that was equal to the product of (a) the number of Peraso Shares subject to the Peraso Options immediately before the closing of the Arrangement and (b) the Exchange Ratio, rounded down to the nearest whole number of shares of common stock.

Upon the closing of the Arrangement, an aggregate of 9,295,097 Exchangeable Shares and 3,558,151 shares of common stock were issued to the holders of Peraso Shares. Of such shares, pursuant to the terms of the Agreement, the Company held in escrow an aggregate of 1,312,878 Exchangeable Shares and 502,567 shares of common stock

13

(collectively, the Escrow Shares). The Escrow Shares are escrowed pursuant to the terms of an escrow agreement on a pro rata basis from the aggregate consideration received by the holders of Peraso Shares, subject to the offset by the Company for any losses in accordance with the Agreement. Such Escrow Shares shall be released, subject to any offset claim, upon the satisfaction of the earlier of: (a) any date following the first anniversary of December 17, 2021 and prior to December 17, 2024 where the volume weighted average price of the common stock for any 20 trading days within a period of 30 consecutive trading days is at least $8.57 per share, subject to adjustment for stock splits or other similar transactions; (b) the date of any sale of all or substantially all of the assets or shares of the Company; or (c) the date of any bankruptcy, insolvency, restructuring, receivership, administration, wind-up, liquidation, dissolution, or similar event involving the Company. All and any voting rights and other stockholder rights, other than with respect to dividends and distributions, with respect to the Escrow Shares are suspended until the Escrow Shares are released from escrow.

In connection with the Arrangement, on December 15, 2021, the Company filed the Certificate of Designation of Series A Special Voting Preferred Stock with the Secretary of State of the State of Delaware to designate Series A Special Voting Preferred Stock (the Special Voting Share) in accordance with the terms of the Arrangement Agreement in order to enable the holders of Exchangeable Shares to exercise their voting rights. Each Exchangeable Share is exchangeable for one share of common stock of the Company and while outstanding, the Special Voting Share enables holders of Exchangeable Shares to cast votes on matters for which holders of the common stock are entitled to vote, and by virtue of the share terms relating to the Exchangeable Shares, to receive dividends that are economically equivalent to any dividends declared with respect to the shares of common stock.

The Exchangeable Shares, which can be converted into common stock at the option of the holder and have the same voting rights as common stock, are similar in substance to shares of common stock and, therefore, have been included in the determination of outstanding common stock.

Reverse Acquisition Determination

Pursuant to ASC 805, the transaction was accounted for as a reverse acquisition because: (i) the stockholders of Peraso Tech owned the majority of the outstanding common stock of the Company after the share exchange; (ii) Peraso Tech appointed a majority of the Company’s board of directors; and (iii) Peraso Tech determined the officers of the Company.

Measuring the Consideration Transferred

In the reverse acquisition, the accounting acquirer did not issue any consideration to the accounting acquiree, rather the accounting acquiree issued its equity shares to the owners of the accounting acquirer in exchange for the accounting acquirer’s shares. The acquisition date fair value of the consideration transferred by the accounting acquirer for its interest in the accounting acquiree was calculated by Peraso Tech, as the fair value of the consideration effectively transferred. In accordance with ASC 805, the consideration effectively transferred between the Company (a public company as the accounting acquiree) and Peraso Tech (a private company as the accounting acquirer), was calculated as the fair value of the Company’s equity including the fair value of its common shares outstanding and its warrants, plus the portion of the share-based award fair value allocated to the pre-combination service of the accounting acquiree’s awards. The fair value of the total consideration effectively transferred was determined to be $37.6 million.

The following table summarizes the final allocation of the purchase price to the net assets acquired based on the respective fair value of the acquired assets and assumed liabilities of the accounting acquiree, which is the Company.

14

|  | December 31, |
|  | 2021 |
Assets: |  | (in thousands) |
Cash, cash equivalents and investments |  | $ | 19,064 |
Other current assets |  |  | 2,558 |
Other assets |  |  | 833 |
Intangibles |  |  |  |
Developed technology |  |  | 5,726 |
Customer relationships |  |  | 2,556 |
|  |  | 8,282 |
Goodwill |  |  | 9,946 |
Liabilities: |  |  |  |
Current liabilities |  |  | 3,056 |
|  | $ | 37,627 |

Unaudited proforma results of operations for the three months ended March 31, 2021 are included below as if the business combination occurred on January 1, 2021. This summary of the unaudited pro forma results of operations is not necessarily indicative of what the Company’s results of operations would have been had Peraso Tech been acquired at the beginning of 2021, nor does it purport to represent results of operations for any future periods.

|  | Three Months Ended |
|  | March 31, 2021 |
|  | (in thousands) |
Revenue |  | $ | 2,439 |
Net loss |  | $ | (5,526 | )

Note 3: Fair Value of Financial Instruments

The estimated fair values of financial instruments outstanding were (in thousands):

|  | March 31, 2022 |
|  |  |  |  |  | Unrealized |  |  | Unrealized |  |  | Fair |
|  | Cost |  |  | Gains |  |  | Losses |  |  | Value |
Cash and cash equivalents |  | $ | 3,791 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,791 |
Short-term investments |  |  | 6,001 |  |  |  | — |  |  |  | (8 | ) |  |  | 5,993 |
Long-term investments |  |  | 2,428 |  |  |  | — |  |  |  | (29 | ) |  |  | 2,399 |
|  | $ | 12,220 |  |  | $ | — |  |  | $ | (37 | ) |  | $ | 12,183 |

|  | December 31, 2021 |
|  |  |  |  |  | Unrealized |  |  | Unrealized |  |  | Fair |
|  | Cost |  |  | Gains |  |  | Losses |  |  | Value |
Cash and cash equivalents |  | $ | 5,893 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,893 |
Short-term investments |  |  | 9,276 |  |  |  | — |  |  |  | (9 | ) |  |  | 9,267 |
Long-term investments |  |  | 2,935 |  |  |  | — |  |  |  | (7 | ) |  |  | 2,928 |
|  | $ | 18,104 |  |  | $ | — |  |  | $ | (16 | ) |  | $ | 18,088 |

15

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):

|  | March 31, 2022 |
|  | Fair Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Money market funds |  | $ | 41 |  |  | $ | 41 |  |  | $ | — |  |  | $ | — |
Corporate notes and commercial paper |  | $ | 8,392 |  |  | $ | — |  |  | $ | 8,392 |  |  | $ | — |
|  | $ | 8,433 |  |  | $ | 41 |  |  | $ | 8,392 |  |  | $ | — |

|  | December 31, 2021 |
|  | Fair Value |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Money market funds |  | $ | 1,159 |  |  | $ | 1,159 |  |  | $ | — |  |  | $ | — |
Corporate notes and commercial paper |  | $ | 12,195 |  |  | $ | — |  |  | $ | 12,195 |  |  | $ | — |

There were no transfers in or out of Level 1 and Level 2 securities during the three months ended March 31, 2022 or December 31, 2021.

Note 4. Balance Sheet Detail

|  | March 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
|  | (in thousands) |
Inventories: |  |  |  |  |  |  |  |
Raw materials |  | $ | 1,408 |  |  | $ | 879 |
Work-in-process |  |  | 2,327 |  |  |  | 2,170 |
Finished goods |  |  | 786 |  |  |  | 775 |
|  | $ | 4,521 |  |  | $ | 3,824 |

Note 5. Commitments and Contingencies

Leases

The Company has three facility leases that it accounts for under ASC 842, and these include the operating leases for its corporate facility in San Jose, California, and facilities in Toronto and Waterloo, Ontario, Canada. The San Jose lease expires in July 2022, and the Waterloo and Toronto leases expire in September 2022 and December 2023, respectively. On March 1, 2022 the Company entered into a 36 month finance lease agreement for the lease of equipment resulting in the recognition of a right-of-use asset and lease liability on the balance sheet of approximately $274,000.

The right-to-use assets and corresponding liabilities for the facility leases were measured at the present value of the future minimum lease payments. The discount rate used to measure the lease assets and liabilities were 8%. Lease expense is recognized on a straight-line basis over the lease term.

Future minimum payments under the leases at March 31, 2022 are listed in the table below (in thousands):

16

|  |  |  |  | Three Months Ended |
|  |  |  |  | March 31, |
|  |  |  |  | 2022 |
Right-of-use assets: |  |  |  |  |  |  |
Operating leases |  |  |  |  | $ | 496 |
Finance lease |  |  |  |  |  | 274 |
Total right-of-use assets |  |  |  |  | $ | 770 |
Lease liabilities: |  |  |  |  |  |  |
Operating leases |  |  |  |  | $ | 559 |
Finance lease |  |  |  |  |  | 274 |
Total lease liabilities |  |  |  |  | $ | 833 |

|  |  |  |  | Operating |
Year ending December 31, |  |  |  |  | leases |
2022 |  |  |  |  | $ | 292 |
2023 |  |  |  |  |  | 305 |
Total future lease payments |  |  |  |  |  | 597 |
Less: imputed interest |  |  |  |  |  | (38 | )
Present value of lease liabilities |  |  |  |  | $ | 559 |

|  |  | Three Months Ended |
|  |  | March 31, |
|  |  | 2022 |  |  | 2021 |
Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |  |  |  |
Operating cash flows for leases |  | $ | 129 |  |  | $ | 71 |

Rent expense was approximately $0.1 million for each of the three month periods ended March 31, 2022 and 2021. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs related to the leased facilities and equipment.

Indemnification

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the three months ended March 31, 2022 and 2021 related to these indemnifications.

The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.

Product warranties

The Company warrants certain of its products to be free of defects generally for a period of three years. The Company estimates its warranty costs based on historical warranty claim experience and includes such costs in cost of net revenues. Warranty costs were not material for the three months ended March 31, 2022 and 2021.

17

Legal Matters

The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Note 6. Business Segments, Concentration of Credit Risk and Significant Customers

The Company determined its reporting units in accordance with ASC 280, Segment Reporting (ASC 280). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.

Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.

The Company recognized revenue from shipments of product, licensing of its technologies and performance of services to customers by geographical location as follows (in thousands):

|  | Three Months Ended |
|  | March 31, |
|  | 2022 |  |  | 2021 |
North America |  | $ | 2,375 |  |  | $ | 55 |
Hong Kong |  |  | 290 |  |  |  | 475 |
Taiwan |  |  | 312 |  |  |  | 565 |
Japan |  |  | 293 |  |  |  | — |
Rest of world |  |  | 133 |  |  |  | 6 |
Total net revenue |  | $ | 3,403 |  |  | $ | 1,101 |

Customers who accounted for at least 10% of total net revenue were:

|  | Three Months Ended
|  | March 31,
|  | 2022 |  | 2021
Customer A |  | 37% |  | *
Customer B |  | 24% |  | *
Customer C |  | * |  | 41%
Customer D |  | * |  | 51%

* | Represents less than 10%

Three customers accounted for 67% of accounts receivable as of March 31, 2022. Three customers accounted for 96% of accounts receivable as of December 31, 2021.

18

Note 7. Income Tax Provision

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.

The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2015 to 2020 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2011 to 2020. As of March 31, 2022, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

Note 8. Stock-Based Compensation

Common Stock Equity Plans

In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. No new awards may be made under the Amended 2010 Plan.

In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares were initially reserved for issuance.

In November 2021, in connection with the approval of the Arrangement, the Company’s stockholders approved an amendment increasing the number of shares reserved for issuance under the 2019 Plan by 3,106,937 shares.

Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

In connection with the Arrangement, the Company assumed the Peraso Technologies Inc. 2009 Share Option Plan (the 2009 Plan) and all outstanding options granted pursuant to the terms of the 2009 Plan. Each outstanding, unexercised and unexpired option under the 2009 Plan, whether vested or unvested, was assumed by the Company and converted into options to purchase shares of the Company’s common stock and became exercisable by the holder of such option in accordance with its terms, with (i) the number of shares of common stock subject to each option multiplied by the Exchange Ratio and (ii) the per share exercise price upon the exercise of each option divided by the Exchange Ratio. In connection with the Arrangement, no further awards will be made under the 2009 Plan.

The 2009 Plan, the Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.”

Stock-Based Compensation Expense

At March 31, 2022, the unamortized compensation cost was approximately $11.4 million related to stock options and is expected to be recognized as expense over a weighted average period of approximately 3 years. The unamortized compensation cost, at March 31, 2022, was $0.2 million related to restricted stock units and is expected to be recognized as expense over a weighted average period of approximately 1.6 years.

For the three months ended March 31, 2022 and 2021, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions.

19

Valuation Assumptions and Expense Information for Stock-Based Compensation

There were no stock options granted or exercised during the three months ended March 31, 2022 and 2021.

Common Stock Options and Restricted Stock

The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control (as defined in the 2019 Plan) of the Company.

The following table summarizes the activity in the shares available for grant under the Plans during the three months ended March 31, 2022 (in thousands, except exercise price):

|  |  | Options Outstanding |
|  |  |  |  |  |  | Weighted |
|  |  |  |  |  |  | Average |
|  |  | Number of |  |  | Exercise |
|  |  | Shares |  |  | Prices |
Balance as of December 31, 2021 |  |  |  | 1,558 |  |  | $ | 3.49 |
Options cancelled |  |  |  | (13 | ) |  | $ | 10.98 |
Balance as of March 31, 2022 |  |  |  | 1,545 |  |  | $ | 3.43 |

A summary of RSU activity under the Plans is presented below (in thousands, except for fair value):

|  |  |  |  |  | Weighted |
|  |  |  |  |  | Average |
|  | Number of |  |  | Grant-Date |
|  | Shares |  |  | Fair Value |
Non-vested shares as of December 31, 2021 |  |  | 88 |  |  | $ | 4.84 |
Vested |  |  | (13 | ) |  | $ | 3.70 |
Non-vested shares as of March 31, 2022 |  |  | 75 |  |  | $ | 5.67 |

The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2022 (in thousands, except contractual life and exercise price):

|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  |  | Weighted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | Average |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | Remaining |  |  | Weighted |  |  |  |  |  |  | Weighted |  |  |  |  |
|  |  |  |  |  | Contractual |  |  | Average |  |  |  |  |  |  | Average |  |  | Aggregate |
|  | Number |  |  | Life |  |  | Exercise |  |  | Number |  |  | Exercise |  |  | Intrinsic |
Range of Exercise Price |  | Outstanding |  |  | (in Years) |  |  | Price |  |  | Exercisable |  |  | Price |  |  | value |
$1.57 - $14.99 |  |  | 1,534 |  |  |  | 8.18 |  |  | $ | 2.65 |  |  |  | 621 |  |  | $ | 2.50 |  |  | $ | 84 |
$15.00 - $25.59 |  |  | 4 |  |  |  | 1.49 |  |  | $ | 15.00 |  |  |  | 4 |  |  | $ | 15.00 |  |  | $ | — |
$25.60 - $143.99 |  |  | 1 |  |  |  | 2.42 |  |  | $ | 50.00 |  |  |  | 1 |  |  | $ | 50.00 |  |  | $ | — |
$144.00 - $409.99 |  |  | 5 |  |  |  | 4.40 |  |  | $ | 144.00 |  |  |  | 5 |  |  | $ | 144.00 |  |  | $ | — |
$410.00 - $924.00 |  |  | 1 |  |  |  | 3.00 |  |  | $ | 410.00 |  |  |  | 1 |  |  | $ | 410.00 |  |  | $ | — |
$1.57 - $924.00 |  |  | 1,545 |  |  |  | 8.15 |  |  | $ | 3.43 |  |  |  | 632 |  |  | $ | 4.42 |  |  | $ | 84 |

20

Note 9. Equity

Warrants

As of March 31, 2022, the Company had the following warrants outstanding (share amounts in thousands):

Type |  | Number of Shares |  |  | Exercise Price |  |  | Expiration
Common stock |  |  | 33 |  |  | $ | 47.00 |  |  | January 2023
Common stock |  |  | 101 |  |  | $ | 2.40 |  |  | October 2023

Note 10. Debt

Loan Facilities

On February 5, 2021, March 5, 2021 and September 17, 2021 the Company raised additional funds from the second, third and fourth draws under the SRED financing of $274,715 (CDN$350,000), $274,715 (CDN$350,000) and $745,655 (CDN$950,000) respectively, totaling year to date gross proceeds of $1,295,085 (CDN$1,650,000) net of financing fees of $32,770 (CDN$41,750). The loan agreement for all tranches carried an interest rate of 1.6% per month, compounded monthly (20.98%). The loan was sanctioned against the Company’s tax credit refund.

The first, second and third draws, including interest of $136,900 (CDN$174,417), were repaid through proceeds from the Company’s tax credit refund of $1,093,230 (CDN$1,392,831) and the balance of $184,558 (CDN$ 235,132) was paid from the fourth draw. The remaining loan balance, including interest, of $816,964 (CDN$1,044,177) was repaid on December 16, 2021.

Interest expense of $513,438 for the three months ended March 31, 2021 consisted of, i) $348,134 of amortization of debt discount and $120,950 of interest expense on the convertible debt and ii) $44,354 of interest expense on the SRED financing.

21

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising effort., the impacts of COVID-19 on our business, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our annual report on Form 10-K for the year ended December 31, 2021 and the risk factors described below under Item 1A of this Form 10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.

Overview

We were formerly known as MoSys, Inc. (MoSys) and were incorporated in California in 1991 and reincorporated in Delaware in 2000. On September 14, 2021, we and our subsidiaries, 2864552 Ontario Inc. and 2864555 Ontario Inc., entered into an Arrangement Agreement (the Arrangement Agreement) with Peraso Technologies Inc. (Peraso Tech), a corporation existing under the laws of the province of Ontario, to acquire all of the issued and outstanding common shares of Peraso Tech (the Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures and common share purchase warrants of Peraso Tech, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario). On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, the Arrangement was completed and the Company changed its name to “Peraso Inc.” and began trading on the Nasdaq Stock Market under the symbol “PRSO.”

For accounting purposes, the legal subsidiary, Peraso Tech, has been treated as the accounting acquirer and we, the legal parent, have been treated as the accounting acquiree. The transaction has been accounted for as a reverse acquisition in accordance with Accounting Standards Codification (ASC) No. 805, Business Combinations (ASC 805). Accordingly, the financial condition and results of operations discussed herein are a continuation of Peraso Tech’s financial results prior to December 17, 2021 and exclude the financial results of us prior to December 17, 2021. See Note 2 to the condensed consolidated financial statements for additional disclosure.

Our strategy and primary business objective is to be a profitable, IP-rich fabless semiconductor company offering integrated circuits (ICs), modules and related non-recurring engineering services. We specialize in the development of mmWave semiconductors, primarily in the 60 GHz spectrum band for 802.11ad/ay compliant devices and in the 28/39 GHz spectrum bands for 5G-compliant devices. We derive our revenue from selling semiconductor devices, as well as modules based on using those mmWave semiconductor devices. We have pioneered a high-volume mmWave production test methodology using standard low cost production test equipment. It has taken us several years to refine performance of this production test methodology, and we believe this places us in a leadership position in addressing operational challenges of delivering mmWave products into high-volume markets. During 2021, we augmented our business model and began selling complete mmWave modules. The primary advantage provided by a module is the silicon and the antenna are integrated into a single device. A differentiating characteristic of mmWave technology is that the radio frequency amplifiers must be as close as possible to the antenna to minimize loss, and, by providing a module, we can guarantee the performance of the amplifier/antenna interface.

We also acquired a memory product line, marketed under the Accelerator Engine name and that comprises our Bandwidth Engine and Programmable HyperSpeed Engine IC products, which integrate our proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. As we are not developing new memory products, from a product development perspective, we continue to leverage our current technologies and core competencies to expand our product offerings without incurring significant additional research and development (R&D) expenses.

22

We incurred net losses of approximately $6.8 million for the three months ended March 31, 2022 and $10.8 million for the year ended December 31, 2021 and had an accumulated deficit of approximately $124.0 million as of March 31, 2022. These and prior year losses have resulted in significant negative cash flows and have required us to raise substantial amounts of additional capital during this period.

We expect to incur operating losses and will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.

COVID-19

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.

Since March 2020, certain jurisdictions in which we operate have issued ’shelter-in-place” orders. We have complied with these orders and, when such orders were in place, minimized business activities at our facilities. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity.

We remain diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. The ultimate impact of the COVID-19 pandemic on our business and results of operations is uncertain and difficult to predict, and we are closely monitoring impacts, especially to customer programs and our supply chain. We have and continue to experience longer lead times for certain components used to manufacture our products. While we believe that our operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could negatively impact our business, results of operations, financial condition and cash flows.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. Our ability to raise additional capital to support operations in the future may be impacted, and we may be unable to access the capital markets and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

For additional information on risks that could impact our future results, please refer to “Risk Factors” in Part II, Item 1A. of this quarterly report on Form 10-Q.

Sources of Revenue

Product revenue

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of our contracts have a single performance obligation to transfer products. Accordingly, we recognize revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. We sell our products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less.

We may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

License and other

Our licensing contracts typically provide for royalties based on the licensee’s use of our memory technology in its currently shipping commercial products. We estimate its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are received in the subsequent quarter. We also generate revenue from licensing

23

our technology. We recognize license fees as revenue at the point of time when the control of the license has been transferred and we have no continuing performance obligations to the customer.

Engineering services revenue

Engineering and development contracts with customers generally contain a single performance obligation that is delivered over time. Revenue is recognized using an output method that is consistent with the satisfaction of the performance obligation as a measure of progress.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our annual report on Form 10-K for the year ended December 31, 2021. As of March 31, 2022, there have been no material changes to our significant accounting policies and estimates.

Results of Operations

Net Revenue

|  | March 31, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Product -three months ended |  | $ | 3,204 |  |  | $ | 1,051 |  |  | $ | 2,153 |  |  |  | 205 | %
Percentage of total net revenue |  |  | 94 | % |  |  | 95 | % |  |  |  |  |  |  |  |

Product revenue increased for the three months ended March 31, 2022 compared with the same period of 2021 primarily due to a full quarter contribution of revenues from our memory IC products and increased shipments of our mmWave module products. We commenced selling our module products in the second quarter of 2021. We expect revenues to increase in 2022, as we expect increased sales of our mmWave products and full-year contribution of revenues from our memory products.

|  | March 31, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
License and other -three months ended |  | $ | 199 |  |  | $ | 50 |  |  | $ | 149 |  |  |  | 298 | %
Percentage of total net revenue |  |  | 6 | % |  |  | 5 | % |  |  |  |  |  |  |  |

License and other includes royalty, non-recurring engineering (NRE), services and licenses revenues. The increase in license and other revenue for the three months ended March 31, 2022 compared with the same period of 2021 was primarily due to a full quarter contribution of royalty revenues from licensees of our memory technology.

Cost of Net Revenue and Gross Profit

|  | March 31, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Cost of net revenue -three months ended |  | $ | 1,590 |  |  | $ | 619 |  |  | $ | 971 |  |  |  | 157 | %
Percentage of total net revenue |  |  | 47 | % |  |  | 56 | % |  |  |  |  |  |  |  |

|  | March 31, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
Gross profit -three months ended |  | $ | 1,813 |  |  | $ | 482 |  |  | $ | 1,331 |  |  |  | 276 | %
Percentage of total net revenue |  |  | 53 | % |  |  | 44 | % |  |  |  |  |  |  |  |

24

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of our products.

Cost of net revenue increased for the three months ended March 31, 2022 when compared with the same period in 2021, primarily due to increased shipment volumes of our LineSpeed and Bandwidth Engine IC and mmWave module products. Our module products have higher cost of goods sold per unit and generate lower gross profit margin than our IC products.

Gross profit decreased for the three months ended March 31, 2022 compared with the same period of 2021 due to the increased product shipments.

Research and Development

|  | March 31, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
R&D -three months ended |  | $ | 6,003 |  |  | $ | 2,787 |  |  | $ | 3,216 |  |  |  | 115 | %
Percentage of total net revenue |  |  | 176 | % |  |  | 253 | % |  |  |  |  |  |  |  |

Our R&D expenses include costs related to the development of our products. We expense R&D costs as they are incurred.

The increase for the three months ended March 31, 2022 compared with the same period of 2021 was primarily due to the inclusion of a full quarter of expenses related to the former operations of MoSys, amortization of intangible assets in the first quarter of 2022 and recognition of government wage and rent subsidies in the first quarter of 2021 that reduced operating expenses. We expect that total research and development expenses will increase in 2022 compared with 2021, as we will include the operations of MoSys and increase development of our mmWave products and technologies. In addition, we do not expect to receive any government subsidies in 2022 that would reduce our expenses.

Selling, General and Administrative

|  | March 31, |  |  | Change |
|  | 2022 |  |  | 2021 |  |  | 2021 to 2022 |
|  | (dollar amounts in thousands) |
SG&A -three months ended |  | $ | 2,546 |  |  | $ | 1,307 |  |  | $ | 1,239 |  |  |  | 95 | %
Percentage of total net revenue |  |  | 75 | % |  |  | 119 | % |  |  |  |  |  |  |  |

Selling, general and administrative (SG&A), expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management.

The increase for the three months ended March 31, 2022 compared with the same period of 2021 was primarily due to the inclusion of a full quarter of expenses related to the former operations of MoSys.

Interest expense

Interest expense incurred during the quarter ended March 31, 2021 related to our loans payable, which were repaid during 2021.

Liquidity and Capital Resources; Changes in Financial Condition

Cash Flows

As of March 31, 2022, we had cash, cash equivalents and investments of $12.2 million and working capital of $13.7 million. We believe that cash generated from our liquidity sources will be sufficient to meet both our short-term and long-term working capital and capital expenditure needs for at least the next twelve months.

Net cash used in operating activities was $5.7 million for the first three months of 2022, which primarily resulted from our net loss of $6.8 million and $1.0 million in net changes in assets and liabilities, partially offset by non-cash charges of $0.8 million of depreciation and amortization, $1.2 million of stock based compensation and a $0.1 million

25

loss on disposal of property and equipment. The changes in assets and liabilities primarily related to the timing of accounts receivable collections, purchases of inventory and other vendor payables and prepayments.

Net cash used in operating activities was $1.3 million for the first three months of 2021, which primarily resulted from our net loss of $4.2 million, which was partially offset by $0.9 million in net changes in assets and liabilities and non-cash charges of $1.2 million of stock-based compensation, $0.3 million of depreciation and amortization expenses, $0.3 million amortization of debt discount and $0.2 million of accrued interest. The changes in assets and liabilities primarily related to the timing of accounts receivable collections and other vendor payables and prepayments.

Net cash provided by investing activities of $3.6 million for the three months ended March 31, 2022 represented $4.2 million in proceeds from maturities of short-term investments, partially offset by $0.5 million purchases of short and long-term investments and $0.1 million of purchases of property and equipment. Net cash used in investing activities for the three months ended March 31, 2021 represented approximately $9,000 of purchases of property and equipment.

Net cash used in financing activities for the three months ended March 31, 2022 consisted of taxes paid to net share settle equity awards.

Net cash provided by financing activities for the three months ended March 31, 2021 consisted of net proceeds received from an unsecured loan.

Our future liquidity and capital requirements are expected to vary from quarter-to-quarter, depending on numerous factors, including:

| • | level of revenue;

| • | cost, timing and success of technology development efforts;

| • | inventory levels, timing of product shipments and length of billing and collection cycles;

| • | fabrication costs, including mask costs, of our ICs, currently under development:

| • | variations in manufacturing yields, material lead time and costs and other manufacturing risks;

| • | costs of acquiring other businesses and integrating the acquired operations; and

| • | profitability of our business.

26

Working Capital

Our primary need for liquidity is to fund working capital requirements of our businesses, capital expenditures and for general corporate purposes. We expect our cash expenditures to exceed receipts in 2022, as we do not expect our revenues will be sufficient to offset our working capital requirements. We incurred a net loss of approximately $6.8 million for the three months ended March 31, 2022 and had an accumulated deficit of approximately $124.0 million as of March 31, 2022. These and prior year losses have resulted in significant negative cash flows and have required us to raise substantial amounts of additional capital during this period. To date, we have primarily financed our operations through multiple equity offerings, issuances of convertible debentures, utilization of loan facilities and government subsidies and credits. However, there can be no assurance that our capital is sufficient to fund operations until such time as we begin to achieve positive cash flows. We have an effective shelf registration statement under which we could sell additional securities without advance notice.

We may need to raise additional capital, but there can be no assurance that such funding will be available to us on favorable terms, if at all. The failure to raise capital when needed could have a material adverse effect on our business and financial condition. We may not be able to obtain additional financing as needed on acceptable terms, or at all, which may require us to reduce our operating costs and other expenditures, including reductions of personnel, salaries and capital expenditures. Alternatively, or in addition to such potential measures, we may elect to implement additional cost reduction actions as we may determine are necessary and in our best interests. Any such actions undertaken might limit our opportunities to realize plans for revenue growth and we might not be able to reduce our costs in amounts sufficient to achieve break-even or profitable operations.

If we were to raise additional capital through sales of our equity securities, our stockholders would suffer dilution of their equity ownership. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could harm our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

| • | develop or enhance our products;

| • | expand our product development and sales and marketing organizations;

| • | acquire complementary technologies, products or businesses;

| • | expand operations;

| • | hire, train and retain employees; or

| • | respond to competitive pressures or unanticipated working capital requirements.

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our existing operations or R&D plans.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity or capital resources.

Recent Accounting Pronouncements

See Note 1 to the condensed consolidated financial statements for a discussion of recent accounting policies.

27

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of March 31, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the three months ended March 31, 2022, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. Legal Proceedings

The discussion of legal matters in Note 4 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading “Legal Matters” is incorporated by reference in response to this Part II, Item 1.

ITEM 1A. Risk Factors

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. There have been no material changes with respect to the risk factors disclosed under Item 1A of our annual report on Form 10-K for the year ended December 31, 2021, which we filed with the SEC on March 31, 2022.

28

ITEM 6. Exhibits

(a) | Exhibits |
| 31.1* | Rule 13a-14 certification
| 31.2* | Rule 13a-14 certification
| 32.1** | Section 1350 certification s
| 101* | The following financial information from Peraso Inc.’s quarterly report on Form 10-Q for the period ended March 31, 2022, filed with the SEC on May 13, 2022, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2022 and 2021, (ii) the Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021, (iii) the Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 and 2021, (iv) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021, and (v) Notes to Condensed Consolidated Financial Statements.
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith.

**Furnished herewith.

29

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 13, 2022 |  | PERASO INC.
| By: | /s/ Ronald Glibbery
|  | Ronald Glibbery
|  | Chief Executive Officer (Principal Executive Officer)
| By: | /s/ James W. Sullivan
|  | James W. Sullivan
|  | Chief Financial Officer
|  | (Principal Financial and Accounting Officer)

30